TEMTempus AI Inc
$60.81
$0.54
(0.90%)
EarningsAug 7
Mkt Cap$10.82B
Vol1.52M
As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data PR Newswire NEW YORK, July 1, 2026 Issued on behalf...
PR Newswire
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with Angiosarcoma Awareness, Inc. to accelerate data-driven research in angiosarcoma, one of the rarest and most aggressive...
Business Wire
Should You Retain Tempus AI Stock In Your Portfolio Now?
TEM's diagnostics growth and expanding data deals support momentum, but sizable GAAP losses and execution challenges could keep shares volatile.
Zacks
16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap
16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap 16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap PR Newswire TORONTO, ON, June 16, 2026 Issued on behalf of Ventripoint Diagnostics Ltd.As the number of...
PR Newswire
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of...
Business Wire
Genetics in Medicine Open Study Demonstrates How Ambry Genetics ExomeReveal RNA Testing Can Improve Diagnostic Clarity in Exome Testing
Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrating the potential for variant-specific RNA testing to provide greater clarity for patients who receive a variant of uncertain significance...
Business Wire
Great News: This Explosive Healthcare Stock Could Be a Powerful Artificial Intelligence Winner
Tempus AI (NASDAQ: TEM) is trying to build more than a diagnostics business. Its growing healthcare data platform, artificial intelligence tools, FDA progress, and pharma partnerships could create meaningful upside if the company can scale profitably. But the stock already reflec...
Nasdaq News: Markets
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at 2:00...
Business Wire
Why Is Tempus (TEM) Down 11.2% Since Last Earnings Report?
Tempus (TEM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
<
1
2
...
>
Advertisement|Remove ads.
Latest TEM News
ViewTEM Stock Slips Overnight: CEO-Linked $9.6M Share Sale Puts A Cloud Over 'AI As Physician' Story
Stocktwits
As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
PR Newswire
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
Business Wire
Advertisement|Remove ads.